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Sofosbuvir, Velpatasvir, and Voxilaprevir
for Treatment of Recurrent Hepatitis
C Virus Infection After Liver
Transplantation
Maria G. Cardona-Gonzalez,1 Jason D. Goldman,1,2 Lawrence Narayan,1 Diana M. Brainard3, and Kris V. Kowdley1

There are limited data on direct-acting antiviral (DAA) treatment options for previously treated patients with recurrent genotype 3 (GT3) hepatitis C virus (HCV) after liver transplantation. Sofosbuvir/velpatasvir/voxilaprevir (SOF/
VEL/VOX) is currently approved for treatment of HCV in patients with prior treatment with DAAs. We report the
first published experience using SOF/VEL/VOX after liver transplantation for a DAA-experienced patient with severe hepatitis due to early recurrent GT3 HCV. The patient was treated with SOF/VEL/VOX that was extended to
a total duration of 16 weeks and was intensified with ribavirin (RBV) starting at week 8 due to persistent viremia
during treatment. Sustained virologic response at 12 weeks (SVR12) after treatment completion was achieved. SOF/
VEL/VOX was well tolerated, and immediate drug–drug interaction (DDI) with tacrolimus (TAC) was not evident.
Due to improvement in liver metabolic function with increasing TAC clearance, TAC dose adjustment was required
throughout the treatment course. Conclusion: SOF/VEL/VOX can be considered for treatment of recurrent HCV
after transplantation. Further study is needed to establish safety and efficacy and define treatment duration in difficult-to-treat populations. (Hepatology Communications 2018;2:1446-1450).

D

irect-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection
have dramatically changed the landscape to
treat recurrent HCV after orthotopic liver transplantation (OLT). Drug–drug interactions (DDIs) may
influence the use of DAAs for treatment of HCV postOLT and may pose challenges to successful dosing of
DAAs or anti-rejection medications. SOF/VEL/VOX
is currently approved for treatment of HCV in patients
with prior treatment with DAAs.(1) However, to our
knowledge, use of this regimen has not been described

in the post-OLT setting. We report our experience in
using sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/
VOX) to treat a DAA-experienced patient with severe
hepatitis due to early recurrent genotype 3 (GT3) HCV.

Patient and Methods
CASE REPORT

A 61-year-old male with a past medical history
of diabetes, hypertension, and chronic back pain was

Abbreviations: AASLD-IDSA, American Association for the Study of Liver Diseases–Infectious Disease Society of America; ALT, alanine
aminotransferase; CYP3A4, cytochrome P450 3A4; DAA, direct-acting antiviral; DDI, drug–drug interaction; EOT, end of treatment; GLE/
PIB, glecaprevir/pibrentasvir; GT3, genotype 3; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; OLT, orthotopic liver transplantation;
P-gp, permeability glycoprotein; POD, postoperative day; RBV, ribavirin; SOF/VEL/VOX, sofosbuvir/velpatasvir/voxilaprevir; SVR, sustained
virologic response; TAC, tacrolimus.
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diagnosed with GT3 HCV in 1995. By January 2014,
he had developed biopsy-proven cirrhosis; he had
interlukin (IL) 28B GT CT.
The patient was first treated for HCV in February
2014 with SOF and ribavirin (RBV) for 16 weeks as
part of the Boson Study.(2) He achieved undetectable
HCV RNA by week 8 through the end of treatment
(EOT). However, HCV viremia recurred at 4 weeks
after EOT, and he was subsequently retreated with
SOF, RBV, and pegylated interferon alfa-2a for 12
weeks. The patient developed anemia, insomnia, and
fatigue but completed the treatment regimen. HCV
RNA was undetectable at week 8 and sustained though
EOT, but again viremia recurred at 4 weeks after EOT.
During both these treatments, study investigators and
clinicians assessed that the patient adhered assiduously
to the treatment regimen. No nonstructural protein 5B
(NS5B) resistance-associated substitutions were identified using a 15% deep sequencing cutoff at the baseline
and treatment failure time points for both treatment
attempts. NS5A genotyping was not performed. In
March 2016, the patient was found to have hepatocellular carcinoma (HCC) and was treated with radio frequency ablation and transarterial chemoembolization.
The patient underwent OLT with exception
points for HCC in August 2017. The donor was a
trauma victim who was not HCV infected. Baseline
laboratory testing prior to OLT showed white blood
cell count 12.7 × 103/µL, hemoglobin 14.2 g/dL,
platelets 164 × 103/µL, normal kidney function with
creatinine 1.18 mg/dL, and liver function showing
total bilirubin 0.6 mg/dL, alanine aminotransferase
(ALT) 200 U/L, aspartate aminotransferase 119 U/L,
and alkaline phosphatase 161 U/L. Induction immunosuppression was high-dose methylprednisolone
with taper, and the maintenance immunosuppression regimen included tacrolimus (TAC), mycophenolate mofetil, and prednisone. The immediate
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FIG. 1. Treatment response of patient on DAA therapy with
SOF/VEL/VOX. # indicates an HCV RNA level that was
detected (<15 IU/mL) but below the limit of linear quantitation
for the assay.

postoperative course was uncomplicated, but the
patient was readmitted to the hospital on postoperative day (POD)9 with elevated liver enzymes.
After OLT, ALT spiked to 447 U/L on POD1 and
decreased to nadir 147 U/L on POD6 but increased
to 487 U/L on POD9 (Fig. 1). Total bilirubin was
3.6 mg/dL after transplant, decreased to 0.8 mg/dL
on POD6, and increased only slightly to 0.9 mg/dL
on POD9. Similarly, alkaline phosphatase was also
not elevated. Biopsy showed portal inflammation,
lymphocytic cholangitis, mild steatosis, and no evidence for fibrosis, findings not diagnostic for acute
rejection. POD11 HCV RNA was >100,000,000
IU/mL, verified as GT3, confirming the diagnosis
of acute allograft hepatitis due to recurrent HCV.
The patient started SOF/VEL/VOX for recurrent
HCV on POD15 for a planned treatment course of
12 weeks. Although data in the post-OLT setting
for SOF/VEL/VOX were lacking, this regimen was
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Results

After starting SOF/VEL/VOX, HCV viremia
decayed rapidly with a >4 log10 drop in HCV
RNA by week 2 but with a slower decrease in HCV
RNA through week 8 when HCV RNA was first
undetectable (Fig. 1). Due to detectable viremia at
treatment weeks 4 and 6, the decision was made to
extend therapy to 16 weeks. At week 8 of SOF/VEL/
VOX therapy, RBV was added. At week 10, HCV
RNA was detectable but below the range of linear
quantification for the assay (<15 IU/mL). With the
addition of RBV, the patient developed insomnia,
fatigue, and anemia and required blood transfusion.
Antiviral treatment for HCV was completed in
December 2017, and SVR was demonstrated at 4
and 12 weeks after completing treatment.
Other medications during SOF/VEL/VOX treatment included valganciclovir, zolpidem, omeprazole,
furosemide, insulin, nebivolol, irbesartan, bupropion,
and oxycodone. Neutropenia requiring filgrastim rescue developed in January 2018 and was ascribed to
the anti-cytomegalovirus prophylaxis valganciclovir.
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Effect of SOF/VEL/VOX on TAC Clearance
TAC Level−to−Dose Ratio (ng/mL/mg)

chosen over the SOF/VEL combination(3) due to the
high efficacy of SOF/VEL/VOX (≥95% sustained
virologic response at 12 weeks [SVR12]) in phase
3 studies in DAA-experienced patients infected
with GT3 HCV.(1) Alternatively, options included
in the American Association for the Study of Liver
Diseases–Infectious Disease Society of America
(AASLD/IDSA) guidelines at the time of DAA
regimen initiation (August 2017) included daclatasvir (DCV ) and SOF (DCV + SOF), but guidelines
recommended extension to 24 weeks and addition of
RBV.(4) At the time of regimen selection, AASLDIDSA guidelines did not include a recommendation
for glecaprevir/pibrentasvir (GLE/PIB). Preliminary
results from the MAGELLAN-2 trial of GLE/PIB
in patients after OLT were not yet published but had
been presented at the European Association for the
Study of the Liver (EASL) 2017 international meeting. The MAGELLAN-2 trial did not enroll any
participants experienced in GT3 treatment.(5) In the
context of no clear guidance for the multiple hardto-treat characteristics of our GT3 patient with multiple treatment experiences, we selected SOF/VEL/
VOX as the most potent and likely to be successful.
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FIG. 2. Effect of SOF/VEL/VOX on TAC clearance and liver
metabolic function. The TAC level was normalized to the daily
dose given 1 day prior to TAC level measurement. The TAC levelto-dose ratio is inversely correlated with TAC clearance and liver
metabolic function (see text).(9) An exponential decay curve was
fit to the TAC level-to-dose data, excluding the three normalized
levels immediately after OLT, as these were non-steady-state
measurements, and preceding initiation.

The immunosuppression strategy was not adjusted
a priori before DAA treatment with SOF/VEL/VOX.
TAC trough levels were monitored weekly and adjusted
to goal levels per post-OLT protocol. Initially, no
adjustment of the TAC dose was necessary after starting SOF/VEL/VOX; however, over the course of the
DAA treatment, TAC dose was slowly and progressively
increased in response to weekly trough levels and the
immunosuppression protocol. At DAA initiation, the
daily dose was 2 mg, and at EOT the daily dose was
5 mg, a 150% increase over the course of SOF/VEL/
VOX treatment. A normalized metric of TAC dosing
(TAC level-to-dose ratio) decreased over the course of
treatment (Fig. 2), indicating increasing TAC clearance.

Discussion

To our knowledge, we describe the first use of the
pan-genotypic DAA therapy SOF/VEL/VOX for
treatment of recurrent HCV after OLT. For recurrence in persons with GT3 HCV infection, AASLDIDSA guidelines recommend GLE/PIB or DCV +
SOF; however, data for treatment-experienced persons
in this setting are lacking.(4) The MAGELLAN-2
study of GLE/PIB in posttransplant patients did not
enroll any GT3 treatment-experienced participants.(5)
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Although both GLE/PIB and DCV have potential
to interact with TAC through weak cytochrome P450
3A4 (CYP3A4) inhibition and permeability glycoprotein (P-gp) inhibition, respectively, neither regimen
has been studied in DAA-experienced patients with
GT3 HCV in the posttransplant setting. Treatment
with SOF/VEL/VOX was selected from the available
choices at the time due to our perception that this
regimen would be the most potent in the context of
multiple prior treatment failures and given the relative
paucity of real-world information with GLE/PIB or
DCV + SOF + RBV in the posttransplant setting for
GT3 HCV infection after prior DAA treatment failures. At the time of regimen selection (August 2017),
there was no clear option, and published data on experience with DAAs remain scant in difficult-to-treat
populations, such as posttransplant, GT3, and treatment experienced. Guidelines from AASLD-IDSA(4)
concur with guidelines from EASL(6) in listing SOF/
VEL with weight-based RBV as an alternative regimen for post-OLT treatment in GT3 patients.
Although recent data have suggested excellent outcomes for SOF/VEL without RBV in patients with
GT3 and post-OLT HCV recurrence, we selected
SOF/VEL/VOX on empirical grounds as the most
potent regimen most likely to achieve cure given the
paucity of data on patients similar to ours with DAA
treatment experience, a history of HCC, and concurrent immunosuppression.(7)
Although treatment with SOF/VEL/VOX was
well tolerated and effective, treatment extension to 16
weeks and intensification with the addition of RBV
were undertaken empirically to increase the probability of a successful outcome. Initial response to SOF/
VEL/VOX showed rapid first-order kinetics and
slower second-order kinetics. Detectable HCV RNA
at weeks 4 and 6 prompted therapy extension of SOF/
VEL/VOX and intensification with RBV. Recurrent,
low-level viremia (below the linear detection limit of
the assay) was observed during the treatment course.
Although common during the interferon era, data
have not supported using response-guided therapy
(i.e., treatment decisions based on viral decay kinetics) with DAAs.(8) Nevertheless, the patient’s initial
viral load of >10,000,000 IU/mL and viremia to 6
weeks was not typical of the patients studied in clinical trials, and therefore direct application of these data
to our patient’s unique circumstances did not seem
appropriate.
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A major challenge of HCV treatment after OLT is
the possible DDIs with immunosuppressive therapy.
This is particularly evident with calcineurin inhibitors,
as coadministration with SOF/VEL/VOX and cyclosporine has been shown to substantially increase the
plasma concentration of VOX in healthy adults with
no studies assessing its safety. As a result, the coadministration of SOF/VEL/VOX with cyclosporine is
not recommended. Our patient was given TAC, which
is a substrate for both CYP3A4 and P-gp and also
a weak inhibitor for P-gp. Potential DDIs of TAC
with SOF/VEL/VOX have not been systematically
studied, although significant interactions requiring
empiric dose modification are not anticipated. VOX
is a substrate and inhibitor of P-gp and solute carrier organic anion transporter family member 1B1
(OATP1B1) and OATP1B3 and is slowly metabolized by CYP3A4. Careful monitoring of the TAC
dose after initiation of SOF/VEL/VOX showed no
immediate change in either the TAC level or TAC
level-to-dose ratio, suggesting an absence of clinically
significant DDIs. However, the TAC level-to-dose
ratio continuously decreased over the course of SOF/
VEL/VOX treatment (Fig. 2). This ratio is inversely
related to liver metabolic function or clearance of TAC
and therefore liver enzymatic function.(9) Clearance
of TAC and liver metabolic function increased over
the course of SOF/VEL/VOX treatment. Our experience confirms that a priori TAC dose adjustment
is not necessary, but continued close monitoring of
TAC concentration during DAA therapy with SOF/
VEL/VOX is necessary to avoid subtherapeutic TAC
dosing and the potential for allograft rejection. These
findings suggest that acute hepatitis from recurrent
HCV after OLT affects hepatic metabolic function
and can be reversed with treatment of recurrent HCV.
DAAs have great promise for alleviating the
morbidity and mortality of recurrent HCV after
OLT. Difficult-to-treat populations exist, such as
GT3 and treatment-experienced persons. SOF/
VEL/VOX represents a potent pan-genotypic regimen that proved effective in this situation of multiple treatment failures and did not show clinically
significant DDIs with TAC and other coadministered medications. Response-guided treatment in
the DAA era may still be an important tool in difficult-to-treat persons. Because this was a single case,
it is important to state that we cannot infer safety
and efficacy when applying to a wider population.
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Specifically, we cannot conclude from our experience if SOF/VEL/VOX alone for 12 weeks would
have proved effective without RBV intensification
or duration extension to 16 weeks. Additional data
are needed in the posttransplant setting to further
characterize the safety and efficacy of this regimen in this vulnerable population with high unmet
medical need.
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